Gotham Asset Management’s Gain Therapeutics GANX Stock Holding History

Gotham Asset Management’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-245,896	Closed	-$5.36M	–	1738
2025 Q2	$5.36M	Buy	245,896 +91,912	+60%	+$170K	0.03%	645
2025 Q1	$3.17M	Sell	153,984 -4,171	-3%	-$9.25K	0.03%	654
2024 Q4	$3.74M	Sell	158,155 -176,437	-53%	-$354K	0.04%	582
2024 Q3	$7.38M	Buy	+334,592	New	+$421K	0.08%	382

Other funds holding GANX

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Gotham Asset Management's GANX Position: Q3 2025 in Review

Gotham Asset Management sold out of Gain Therapeutics (GANX) in Q3 2025, closing a stake of 245,896 shares — an estimated $5.36M sold.

Gotham Asset Management first reported a position in GANX in Q3 2024 and held it in 4 quarters. The position peaked at $7.38M in Q3 2024. 38 funds tracked by Wall St. Rank hold GANX as of Q3 2025.

Gotham Asset Management reported no remaining Gain Therapeutics position as of Q3 2025 after selling out during the quarter.
Gotham Asset Management sold 245,896 Gain Therapeutics shares in Q3 2025, an estimated $5.36M.
Gotham Asset Management first reported a position in Gain Therapeutics in Q3 2024 and held it in 4 quarters.
Gotham Asset Management's Gain Therapeutics position peaked at $7.38M in Q3 2024.
38 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2025.

Based on Gotham Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.